MetLife Investment Management’s Design Therapeutics DSGN Stock Holding History

MetLife Investment Management’s Portfolio DSGN Stock Details DSGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$298K	Buy	20,609 +5,360	+35%	+$66.8K	﹤0.01%	2207
2026 Q1	$162K	Hold	15,249	–	–	﹤0.01%	2329
2025 Q4	$143K	Buy	15,249 +4,929	+48%	+$38.6K	﹤0.01%	2439
2025 Q3	$77.7K	Buy	+10,320	New	+$51.7K	﹤0.01%	2740
2025 Q2	–	Sell	-18,962	Closed	-$73.2K	–	2866
2025 Q1	$73.2K	Sell	18,962 -372	-2%	-$1.77K	﹤0.01%	2633
2024 Q4	$119K	Hold	19,334	–	–	﹤0.01%	2538
2024 Q3	$104K	Buy	+19,334	New	+$90.9K	﹤0.01%	2611
2023 Q3	–	Sell	-22,045	Closed	-$139K	–	2914
2023 Q2	$139K	Hold	22,045	–	–	﹤0.01%	2493
2023 Q1	$127K	Hold	22,045	–	–	﹤0.01%	2454
2022 Q4	$226K	Hold	22,045	–	–	﹤0.01%	2177
2022 Q3	$369K	Buy	22,045 +5,160	+31%	+$103K	﹤0.01%	1857
2022 Q2	$236K	Hold	16,885	–	–	﹤0.01%	2197
2022 Q1	$273K	Buy	16,885 +6,021	+55%	+$92.2K	﹤0.01%	2153
2021 Q4	$233K	Buy	+10,864	New	+$187K	﹤0.01%	1962

Other funds holding DSGN

SOCM

SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return

Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

TECP

Trails Edge Capital Partners Atlanta, Georgia $630M AUM

Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return

Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

MetLife Investment Management's DSGN Position: Q2 2026 in Review

MetLife Investment Management increased its Design Therapeutics (DSGN) stake by 35% in Q2 2026, buying an estimated $66.8K and bringing the position to 20,609 shares worth $298K. The position accounts for ﹤0.01% of the portfolio, ranked #2207.

MetLife Investment Management first reported a position in DSGN in Q4 2021 and has held it in 14 quarters since. The position peaked at $369K in Q3 2022. 136 funds tracked by Wall St. Rank hold DSGN as of Q2 2026.

MetLife Investment Management held 20,609 shares of Design Therapeutics worth $298K as of Q2 2026.
MetLife Investment Management bought 5,360 Design Therapeutics shares in Q2 2026, an estimated $66.8K.
Design Therapeutics made up ﹤0.01% of MetLife Investment Management's portfolio in Q2 2026, its #2207 holding.
MetLife Investment Management first reported a position in Design Therapeutics in Q4 2021 and has held it in 14 quarters since.
MetLife Investment Management's Design Therapeutics position peaked at $369K in Q3 2022.
136 funds tracked by Wall St. Rank held Design Therapeutics as of Q2 2026.

Based on MetLife Investment Management's 13F filing for Q2 2026, filed 14 Aug 2026.